Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy

Akebia Therapeutics Inc. (NASDAQ:AKBA) is 1 of the 10 champion penny stocks that could triple your money.

On February 26, Akebia Therapeutics Inc. (NASDAQ:AKBA) outlined its 2026 pipeline enlargement and shared expectations for Vafseo information catalysts successful the $1 cardinal dialysis marketplace during its 4th fourth 2025 net call. The institution reported a full of $227 cardinal successful nett merchandise gross for the year, with Vafseo and Auryxia being large contributors.

hywards/Shutterstock.com

Chief Executive Officer John Butler reported that it was an important twelvemonth for Akebia, peculiarly owed to the commercialization of Vafseo. He besides reported that determination is expanding grounds of Vafseo’s imaginable for becoming modular of attraction successful what is simply a $1 cardinal U.S. accidental post-TDAPA, erstwhile Vafseo is expected to beryllium priced astatine astir parity with ESA pricing.

The institution besides announced its pipeline for uncommon kidney diseases, including an R&D time scheduled for April 2 to sermon mid-stage assets specified arsenic praliciguat and AKB-097. Butler stated:

“At the ASN gathering successful November, we presented a post-hoc hierarchical composite endpoint investigation wherever patients treated with Vafseo experienced a little hazard of dying oregon being hospitalized than patients treated with the ESA comparator.”

On February 25, BTIG reduced the firm’s terms people connected Akebia Therapeutics Inc. (NASDAQ:AKBA) from $5 to $4. The steadfast maintained its Buy standing connected the stock, citing a caller protocol from U.S. Renal Care that impacted dosing practices, starring to a diminution successful transmission inventory and lower-than-expected Q4 gross for Vafseo. It added that the inventory accommodation weighed connected near-term results contempt the company’s broader outlook remaining intact.

Akebia Therapeutics Inc. (NASDAQ:AKBA) concentrates connected the improvement and commercialization of medicines for kidney diseases. Its merchandise portfolio includes Vafseo (vadadustat) and Auryxia. Additionally, it is moving connected AKB-10108 for the attraction of retinopathy of prematurity successful neonates and AKB-9090 for treating cardiac surgery-related acute kidney wounded and acute respiratory distress syndrome, which is undergoing Phase 2 of its objective trial.

While we admit the imaginable of AKBA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.